Brown Advisory Inc. Grows Position in Charles River Laboratories Intl. Inc (CRL)

Brown Advisory Inc. boosted its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 1.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 666,281 shares of the medical research company’s stock after purchasing an additional 12,227 shares during the period. Brown Advisory Inc.’s holdings in Charles River Laboratories Intl. were worth $71,119,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CRL. William Blair Investment Management LLC boosted its position in Charles River Laboratories Intl. by 3,017.9% during the fourth quarter. William Blair Investment Management LLC now owns 1,406,744 shares of the medical research company’s stock valued at $153,968,000 after purchasing an additional 1,361,626 shares during the last quarter. Wells Fargo & Company MN boosted its position in Charles River Laboratories Intl. by 423.6% during the first quarter. Wells Fargo & Company MN now owns 1,249,196 shares of the medical research company’s stock valued at $133,339,000 after purchasing an additional 1,010,618 shares during the last quarter. TimesSquare Capital Management LLC boosted its position in Charles River Laboratories Intl. by 181.1% during the fourth quarter. TimesSquare Capital Management LLC now owns 915,600 shares of the medical research company’s stock valued at $100,212,000 after purchasing an additional 589,900 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Charles River Laboratories Intl. during the first quarter valued at $24,613,000. Finally, Mackenzie Financial Corp boosted its position in Charles River Laboratories Intl. by 15.3% during the fourth quarter. Mackenzie Financial Corp now owns 1,071,178 shares of the medical research company’s stock valued at $117,240,000 after purchasing an additional 142,382 shares during the last quarter. 97.17% of the stock is owned by hedge funds and other institutional investors.

NYSE CRL opened at $111.22 on Friday. Charles River Laboratories Intl. Inc has a fifty-two week low of $94.15 and a fifty-two week high of $119.05. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.78 and a current ratio of 2.07. The stock has a market cap of $5.38 billion, a price-to-earnings ratio of 21.10, a P/E/G ratio of 1.43 and a beta of 0.70.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Thursday, May 10th. The medical research company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.12. The business had revenue of $493.97 million for the quarter, compared to analyst estimates of $480.03 million. Charles River Laboratories Intl. had a return on equity of 24.96% and a net margin of 6.78%. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.29 earnings per share. analysts anticipate that Charles River Laboratories Intl. Inc will post 5.82 earnings per share for the current fiscal year.

A number of analysts recently issued reports on CRL shares. KeyCorp raised Charles River Laboratories Intl. from a “sector weight” rating to an “overweight” rating and lifted their price objective for the company from $115.85 to $130.00 in a research report on Friday, June 15th. Morgan Stanley reissued an “equal weight” rating and set a $102.00 price objective (up previously from $94.00) on shares of Charles River Laboratories Intl. in a research report on Wednesday, March 14th. Mitsubishi UFJ Financial Group assumed coverage on Charles River Laboratories Intl. in a research report on Friday, April 20th. They set a “neutral” rating and a $115.00 price objective for the company. Zacks Investment Research upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $117.00 target price on the stock in a report on Friday, May 11th. Finally, TheStreet upgraded Charles River Laboratories Intl. from a “c+” rating to a “b+” rating in a report on Thursday, May 10th. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $117.71.

In other news, Director George Massaro sold 300 shares of Charles River Laboratories Intl. stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $115.55, for a total value of $34,665.00. Following the transaction, the director now directly owns 14,037 shares in the company, valued at $1,621,975.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Ross Smith sold 945 shares of Charles River Laboratories Intl. stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $104.23, for a total value of $98,497.35. Following the completion of the transaction, the insider now owns 13,723 shares in the company, valued at $1,430,348.29. The disclosure for this sale can be found here. Insiders sold 2,463 shares of company stock worth $263,720 over the last quarter. 2.10% of the stock is currently owned by corporate insiders.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply